Global HER2 Positive Breast Cancer Treatment Market – Industry Trends and Forecast to 2029

HER2 Positive Breast Cancer Treatment Market Analysis and Size

The global HER2 positive breast cancer treatment market is expected to witness significant growth during the forecast period. Breast cancer is the second most common cancer in the world and is the most common cancer in women globally. Human epidermal growth factor receptor 2-positive (HER2+) breast cancer consist of around 20% of breast cancer cases and was associated with poor prognosis in the absence of several effective treatments. The endlessly improving healthcare infrastructure, along with the increase in disposable incomes of people in Asia-Pacific region is expected to make the market grow in the forecast period. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global HER2 positive breast cancer treatment market in the forecast period 2022-2029. The expected CAGR of global HER2 positive breast cancer treatment market  is tend to be around 1.50% in the mentioned forecast period. The market was valued at USD 10.50 billion in 2021, and it would grow upto USD 11.83 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

HER2 Positive Breast Cancer Treatment Market Scope and Segmentation

Market Definition

HER2-positive breast cancer treatment is a type of breast cancer wherein the test confirmed the presence of human epidermal growth factor receptor 2 (HER2), a protein that boosts cancer cells' growth. Breast cancer is not a single disease but a group of numerous different tumor subtypes. Although many subtypes exist, they are usually categorized by the presence or absence of hormonal receptors (HRs), which includes estrogen receptor (ER) and the progesterone receptor (PR), along with human epidermal growth factor receptor 2 (HER2). It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global HER2 Positive Breast Cancer Treatment Market Dynamics

Drivers

• Increase in HER2 Positive Breast Cancer

The rate of HER2-positive (HR+/HER2+ and HR–/HER2+) breast cancer rise from 10–11 in 2020 to 13–14 per 100,000 women in 2030. This boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global esophageal cancer market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Drug Launches

Several drug launches are associated with the creation of opportunities for he market. Approval and launch of premium-priced therapeutics during the forecast period such as two small molecule inhibitors (Ibrance and Piqray), two antibody-drug conjugates (trastuzumab duocarmazine and disitamab vedotin), and a checkpoint inhibitor (Tecentriq) Label expansion of established drugs like Enhertu and Tukysa are benefitting the market growth.

• Higher Indulgence of Immunotherapy

The segment of immunotherapy is projected to gain further attraction during the forecast period. Immunotherapeutics tend to have less adverse effects when compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are most likely to suppress the growth of chemotherapeutics and boost the adoption of immunotherapeutics and other targeted treatments. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are not aware of the knowledge of the appropriate treatment methods for this disease could restraint the growth of the global HER2 positive breast cancer treatment market over a forecast period.

• Patent Expiration of the Drugs

The patent expiration of several drugs hamper the market growth.  Patent expiries of the top brands particularly Perjeta, Herceptin and Kadcyla, which held the majority of sales in 2020 are hampering the market growth.

This global HER2 positive breast cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global HER2 positive breast cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global HER2 Positive Breast Cancer Treatment Market Scope

The global HER2 positive breast cancer treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Others

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

HER2 Positive Breast Cancer Treatment Market Regional Analysis/Insights

The global HER2 positive breast cancer treatment market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global HER2 positive breast cancer treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the rise cases of HER2-positive breast cancer, favourable government policies, and advanced healthcare facilities.

Asia-Pacific dominates the market due to the increase government initiatives and rapidly increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Intestine Cancer Therapeutics Market Share Analysis

The global HER2 positive breast cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global HER2 positive breast cancer treatment market.

Key players operating in the global HER2 positive breast cancer treatment market include:

• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)

SKU-54137